ERBB2 and breast cancer: Lee et al. discovered that concentrations of heat shock protein 90 (HSP90) were highly elevated in drug-resistant BC cells, and a mixture of lapatinib and HSP90 inhibitors represented an advantageous therapeutic strategy for HER2+ patients (Lee et al., 2020).